摘要
目的探讨促性腺激素释放激素激动剂(GnRH-a)与屈螺酮炔雌醇序贯治疗子宫腺肌瘤术后患者的临床效果。方法选择2018年1月至2020年6月我院收治的140例子宫腺肌瘤患者为研究对象,根据治疗方案的不同将其分为对照组和研究组,各70例。两组均接受腹腔镜子宫腺肌瘤病灶切除术,术后对照组给予屈螺酮炔雌醇口服治疗,研究组采取GnRH-a与屈螺酮炔雌醇序贯治疗。比较两组的月经情况、子宫体积、激素、血清Bcl-2、Bax水平、临床疗效及生活质量。结果治疗后,研究组的月经量少于对照组,子宫体积小于对照组,差异具有统计学意义(P<0.05)。治疗后,两组的E2、LH和FSH水平均降低,且研究组低于对照组,差异具有统计学意义(P<0.05)。治疗后,两组的Bcl-2水平均降低,Bax水平均升高,且研究组优于对照组,差异具有统计学意义(P<0.05)。研究组的治疗总有效率高于对照组,差异具有统计学意义(P<0.05)。治疗后,两组的生活质量各维度评分均升高,且研究组高于对照组,差异具有统计学意义(P<0.05)。结论GnRH-a与屈螺酮炔雌醇序贯治疗子宫腺肌瘤术后患者效果显著,能有效改善月经量、子宫体积、激素、Bcl-2和Bax水平,提高生活质量,值得临床推广应用。
Objective To investigate the clinical effect of gonadotropin-releasing hormone agonist(GnRH-a)and drospirosterone ethinylestradiol in sequential treatment of postoperative patients with adenomyoma uteri.Methods A total of 140 patients with adenomyoma uteri admitted in our hospital from January 2018 to June 2020 were selected as the research objects,and the patients were divided into control group and study group according to different treatment regimens,with 70 cases in each group.Both groups received laparoscopic adenomyoma uteri resection.The control group was given oral treatment with drospirosterone ethinylestradiol after operation,and the study group was given sequential treatment with GnRH-a and drospirosterone ethinylestradiol.The menstrual status,uterine volume,hormone,serum Bcl-2 and Bax levels,clinical efficacy and quality of life were compared between the two groups.Results After treatment,the menstrual volume in the study group was less than that in the control group,and the uterine volume was smaller than that in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of E2,LH and FSH in both groups decreased,and those in the study group were lower than the control group,the differences were statistically significant(P<0.05).After treatment,the Bcl-2 level in both groups decreased,and the Bax level increased,and those in the study group were better than the control group,the differences were statistically significant(P<0.05).The total effective rate of treatment in the study group was higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the quality of life scores of all dimensions in the two groups improved,and those in the study group were higher than the control group,the differences were statistically significant(P<0.05).Conclusion GnRH-a and drospirosterone ethinylestradiol in sequential treatment of postoperative patients with adenomyoma uteri has a significant effect,it can effectively ameliorate menstrual volume,uterine volume,hormone,Bcl-2 and Bax levels,and improve the quality of life,which is worthy of clinical promotion and application.
作者
杨艳
尚艳
王彩丽
YANG Yan;SHANG Yan;WANG Caili(Jingbian County People's Hospital,Yulin 718500;the First Hospital of Yulin,Yulin 719000,China)
出处
《临床医学研究与实践》
2022年第8期74-77,共4页
Clinical Research and Practice
关键词
子宫腺肌瘤
促性腺激素释放激素激动剂
屈螺酮炔雌醇
序贯治疗
腹腔镜
adenomyoma uteri
gonadotropin-releasing hormone agonist
drospirosterone ethinylestradiol
sequential treatment
laparoscope
